KTWIY yields 1.46% · JNJ yields 2.13%● Live data
📍 KTWIY pulled ahead of the other in Year 1
Combined, KTWIY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KTWIY + JNJ for your $10,000?
Kurita Water Industries Ltd. provides various water treatment solutions in Japan, Asia, North America, South America, Europe, the Middle East, Africa, and internationally. The Water Treatment Chemicals segment offers boiler water treatment chemicals, cooling water treatment chemicals, wastewater treatment chemicals, process treatment chemicals, reverse osmosis membrane water treatment chemicals, automobile paint booth chemicals, biomass generation related chemicals, civil engineering and construction related chemicals, marine vessel related water treatment chemicals, chemical dosing systems/chemical dosing control systems, and packaged contract services. The Water Treatment Facilities segment offers water treatment equipment and facilities; ultrapure water production systems, tool cleaning, plant cleaning, and soil and groundwater contamination remediation services; and swimming pool related equipment services. This segment also provides ultrapure water production systems, wastewater reclamation systems, and wastewater treatment systems and equipment. It also offers soil and groundwater contamination remediation, plant facilities cleaning, and precision tool cleaning services, as well as water treatment equipment for professional use, products for general household's, and swimming pool-related equipment. The company was incorporated in 1949 and is headquartered in Tokyo, Japan.
Full KTWIY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.